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Dopamine receptor subtypes in renal brush border and basolateral
membranes. Dopamine (DA) modulates renal tubular sodium transport
by actions at both brush border (BBM) and basolateral membranes
(BLM). DA receptors have been demonstrated in proximal tubule but
the subtype of DA receptor in either BBM or BLM has not been
determined. DA-I receptors were quantitated by the specific binding of
'251SCH 23982, a DA-l antagonist (defined by 20 ILM SCH 23390, a
DA-I antagonist) and DA-2 receptors by the specific binding of 3H-
methyl-spiroperidol or 3H-spiroperidol (defined by 30 M trifiuperidol,
a predominantly DA-2 antagonist). The specific binding of '251-SCH
23982 and 3H-methyl-spiroperidol or 3H-spiroperidol were saturable
with time and ligand concentration and reversible. Analysis of
Rosenthal plots by non-linear regression revealed a high affinity site and
a very low affinity site for both BLM and BBM. Maximum receptor
density was similar in BBM and BLM. Competition experiments with
'251ScH 23982 revealed high and low affinity binding sites in both BBM
and BLM. The high affinity site was characteristic of a DA-l receptor.
Competition experiments with 3H-spiroperidol were also suggestive of
DA-2 receptors. DA-l but not DA-2 drugs increased adenylate cyclase
and phospholipase-C activities in both BBM and BLM. However, their
effects were greater in BLM than BBM. We conclude that DA-l and
DA-2 receptors are present in both BBM and BLM in canine kidney.
Renal DA- I receptors are linked to stimulation of both adenylate
cyclase and phospholipase-C activity.
The renal vasodilatory action of exogenously administered
dopamine (DA) and DA-l agonists produces a natriuresis and
diuresis by alterations in peritubular physical forces controlling
renal sodium transport [1, 21. Alterations in water and electro-
lyte excretion, however, induced by these agents can also occur
in the absence of changes in renal blood flow [3—5]. In the dog,
the DA-l agonist fenoldopam increases sodium excretion even
when renal blood flow is not increased [4]. In man, fenoldopam
may also increase sodium excretion by actions at proximal and
distal tubular sites [6]. Several studies have demonstrated direct
renal tubular effect of DA. Chan et al [71 reported that DA
decreases fluid and bicarbonate transport in the proximal con-
voluted tubule (PCT) of the rat perfused in vivo. DA and DA
agonists epinine, A6,7 DTN decrease fluid, sodium, and phos-
phate transport in proximal straight tubule but not in PCT of the
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rabbit perfused in vitro [8, 9]. These effects are blocked by
dopaminergic blockers with greater selectivity for the DA-2
receptor but not by alpha or beta adrenergic or serotonin
antagonists.
DA also induces swelling of rat PCT, presumably by decreas-
ing Na/K ATPase activity at the basolateral membrane [10];
recently these investigators reported that occupation of both
DA-1 and DA-2 receptor subtypes is necessary to inhibit
Na/K ATPase activity [11]. The effects of DA on the luminal
membrane of the proximal tubule is controversial. Laradi,
Sakhrani and Massry [12] reported that DA actually increases
sodium uptake via the luminal Na/H antiport in isolated
proximal tubular cells of the rabbit. In rabbit intestine, DA
added to the serosal surface increased sodium and chloride
transport, an effect blocked by the DA-2 antagonists haloper-
idol and domperidone [13]; addition of DA to the mucosal
surface produced no effect. DA administered into the lumen of
the rat PCT increases fluid reabsorption. This effect is blocked
by the beta adrenergic antagonist propranolol but not by the
DA-2 antagonist, haloperidol [14]. In contrast, Bello-Reuss et al
did not find any effect of intraluminal DA in proximal straight
tubule of the rabbit [8]. Whether the differences in the effect of
DA on sodium transport are related to methodology or effects
on different receptor subtypes remains to be determined.
DA receptors including subtypes DA-1 and DA-2 have been
demonstrated in rabbit and rat renal cortical homogenates [15,
16]. The renal DA-l receptor in the rat and rabbit renal cortex
has been localized, specifically to the proximal convoluted and
straight tubule and cortical collecting duct [15, 17]. The renal
tubular DA-l but not the DA-2 receptor has been linked to
stimulation of adenylate cyclase and phospholipase-C activity
[15—18]. While there is physiological evidence for DA receptors
in brush border[l2, 14] and basolateral membranes [8—11] of the
proximal tubule, the subtype(s) have not been identified. These
studies, therefore, were undertaken to characterize the DA
receptor in canine renal tubular basolateral and brush border
membranes by radioligand binding. In addition, linkages to
adenylate cyclase and phospholipase-C were determined.
Methods
Preparation of basolateral and brush border membranes
Basolateral and brush border membranes were prepared by a
modification of a procedure developed by Liang and Sacktor
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[19]. Adult dogs were anesthetized with sodium pentobarbital
(Nembutal, 50 mg/kg body weight i.v.); the kidneys were
removed and the outer two thirds of the cortex was separated
from the medulla. This procedure has been shown to yield
proximal convoluted to a greater extent than proximal straight
tubules [20, 211. Finely minced cortical tissue was homogenized
in sucrose buffer (sucrose 0.25 M, MgCI2 10 m, and Tris-Cl 5
mM, pH 7.5) at 0 to 4°C with 20 strokes in a Potter-Elvehjem
glass homogenizer and a close-fitting teflon pestle. The homoge-
nate was subjected to a Polytron homogenizer (Brinkmann
Instruments, Westbury, New York, USA; #7, 30 seconds x 3).
The crude homogenate was then centrifuged at 2500 x g for 20
minutes at 0 to 4°C in a Beckman J-2 I B refrigerated centrifuge
with a JA-20 rotor. The fat layer was carefully aspirated off the
top, and the supernatant centrifuged at 24,000 xg for 20
minutes. The resulting supernatant was carefully aspirated and
the membranes swirled free of the dark lower pellet with
sucrose buffer. The membranes were combined and brought up
to a ratio of 8 ml/g original wet weight of kidney cortex with
sucrose buffer. Percoll (Pharmacia, Piscataway, New Jersey,
USA) was added to the crude plasma membranes to achieve a
final concentration of 9% and the resulting mixture was centri-
fuged at 30,000 Xg (the brake on the centrifuge was turned off
to avoid disturbing the layers). The top clear layer was dis-
carded and the top-most dark band was removed. This layer
was composed primarily of basolateral membranes (BLM) as
established by marker enzyme analysis. The clear layer below
the BLM band was discarded and the dark layer at the bottom
of the tube was determined to be primarily brush border
membranes (BBM) also established by marker enzyme analy-
sis. Both the BBM and BLM were brought up in KCI buffer at
a ratio of 8 ml/g original cortex wet weight. The BBM were
further purified by the addition of 4 mri MnCI2, followed by
gentle stirring for 20 minutes at 0 to 4°C and centrifuged at 2500
xg for 20 minutes. The BBM and BLM were pelleted at 30,000
xg for 30 minutes and washed three times with incubation
buffer as indicated. The BLM and BBM were either stored at 0
to 4°C for use the same day in AC and PL-C activation studies
or frozen in liquid nitrogen for radioligand binding experiments.
Characterization of isolated renal cortical cellular
membranes
The purity of the isolated membranes was checked using the
following enzyme markers: Na/K ATPase for BLM, gamma
glutamyl transpeptidase and alkaline phosphatase for BBM,
acid phosphatase for lysosomal membranes, cytochrome c
oxidase for mitochondria and lactate dehydrogenase for cytosol
[19—23]. Na/K ATPase activity was measured by the method
of Swann [24] in which the dephosphorylation of (tris)-p-
nitrophenylphosphate by K-p-nitrophenyIphosphatase (PNP
Pase) was an index of Na/K ATPase activity. This measure-
ment is relatively insensitive to the endogenous phosphate pool
and metabolic competition for ATP [241. Gamma glutamyl
transpeptidase, alkaline phosphatase and lactate dehydroge-
nase were determined on an Automated Clinical Analyzer
(ACA; El Du Pont de Nemours and Co. Wilmington, Delaware,
USA) based on the method of Szasz [25], Bowers and McComb
[26], and Gay, McComb and Bowers [27], respectively. Acid
phosphatase was determined by the procedure of Lansing et al
[28]. Cytochrome c oxidase was assayed by the method of
Wharton and Tzagoloff [29]. Protein concentrations were deter-
mined by the method of Lowry [30] using bovine serum albumin
as a reference protein.
Determination of membrane vesicle orientation
Vesicle orientation of BLM was determined by the procedure
of Kinsella et al [311 and Heeswijk, Geertsen and van Os [32] in
which 0.04% digitonin was used to disrupt the vesicles and
ouabain sensitivity was used to test for sidedness. The orienta-
tion of brush border membrane vesicles was not determined as
their orientation has been shown to be essentially 100% right-
side out [33].
Methods for radioligand binding techniques
Ligands. The DA-l antagonist '251-SCH 23982 (New England
Nuclear, Boston, Massachusetts, USA) was used to study
DA-l receptors. Specific binding was defined by 20 jiM SCH
23390 (Schering Corporation, Kenilworth, New Jersey, USA),
a DA- I antagonist. The DA-2 antagonist 3H-spiroperidol or
3H-methyl-spiroperidol (New England Nuclear) was used to
study DA-2 receptors. Specific binding was defined by 30 jiM
trifluperidol (Janssen Pharmaceutica mc, Piscataway, New
Jersey, USA).
Purity and stability of radioligands. The purity of the com-
pounds was ascertained by radiochromatography. '251-SCH
23982 was developed in chloroform:methanol (4:1), and 3H-
spiroperidol and 3H-methyl-spiroperidol were developed in
chloroform:methanol (9:1) on silica gel 60 plates (Merck).
There was no significant metabolism of the radioligands under
our assay conditions (data not shown).
Radioligand binding studies: Standard binding assay. Stan-
dard assay conditions were used for all binding studies except
where noted. BBM and BLM previously frozen in liquid
nitrogen were thawed on ice, homogenized in a Potter-Elve-
hjem glass teflon homogenizer, and washed three times in
incubation buffer as indicated. The final pellet was rehomoge-
nized in incubation buffer and the protein concentration ad-
justed to about 0.5 to 1 mg proteinlml. The membranes were
sonicated at 0 to 4°C by a Branson Sonifier sonicator (#50 x 30
sec) to disrupt the vesicles. With these procedures there was no
uptake of 22Na suggesting complete vesicle disruption (data
not shown). The binding assay (in polypropylene test tubes)
was started with the addition of 800 jil of membrane suspension
to 100 jil of radioligand (0.5 to 100 nM) and 100 ,td of either
incubation buffer alone or incubation buffer with added unla-
belled ligands. (Unlabelled ligands were added to define non-
specific binding). Under standard assay conditions the incuba-
tion occurred at 25°C in a Dubnoff shaking water bath for 60
minutes. The reaction was terminated by pouring the incubate
over Whatman GF/C glass fiber filters (previously soaked in
polylysine I mg/ml) in a Millipore sampling manifold under
reduced pressure. The incubation tube was immediately rinsed
three times with 3 ml incubation buffer at 0 to 4°C and poured
over the same GF/C filters to wash away any unbound radio-
activity. The filters were then placed in polypropylene scintil-
lation vials with Liquiscint scintillation cocktail (National Di-
agnostics), and radioactive decay (3H or 1251) was measured in
a Beckman LS-180l liquid scintillation spectrophotometer or an
ANSR gamma counter (Abbott Inds., Dallas, Texas, USA).
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Table 1. Specific activity and enrichment of BBM and BLM from canine renal cortex
LDH
Tissue cytosol
Na/KATPase
BLM
GGT Alk phos Acid phos
lysosome
CCO
mitochondriaBBM
CH 0.97 0.07
BLM 0.07 0.02
BBM 0.04 0.002
0.10 0.003
1.30 0.03
0.02 0.002
1.58 0.16
3.42 0.56
17.3 1.3
0.62 0.07
1.60 0.10
3.83 0.55
0.05 0.003
0.04 0.002
0.07 0.003
0.43 0.01
0.15 0.02
0.14 0.01
Fold enrichment from CH
BLM 0.07
BBM 0.04
13.0
0.2
2.2
11.0
2.6
6.2
1.0
1.5
0.3
0.3
Values are the mean SEM of the specific activities for 5 experiments performed in duplicate. Abbreviations are: CH, crude homogenate; BLM,
basolateral membrane; BBM, brush border membrane; LDH, lactate dehydrogenase; GGT, gamma glutamyl transpeptidase; Alk phos, alkaline
phosphatase; acid phos, acid phosphatase; CCO, cytochrome C oxidase. The membrane or organelle for each marker enzyme is indicated.
Enrichment is defined as the specific activity of either BLM or BBM divided by the specific activity of CH. All specific activities are expressed
in LU/liter except for NaKATPase and acid phosphatase, which are expressed in mol p-nitrophenol/min/mg protein.
The efficiencies were 60% and 65%, respectively. Filter blanks
were less than 5% of the total binding at the Kd of the receptor.
Specific binding was defined as the difference between radioli-
gand bound in the absence, and in the presence of unlabelled
ligand. The incubation time of 60 minutes was chosen for
equilibrium based on binding kinetic studies.
Kinetic studies. Association kinetics were studied under
standard assay conditions except as indicated. The concentra-
tion of 3H-methyl-spiroperidol was 2 n and 100 M for
'251SCH 23982, All components of the assay mix were brought
to 25°C for five minutes in a Dubnoff shaking water bath before
starting the binding reaction. The reaction was started by the
addition of membrane suspension. Total and non-specific bind-
ing were determined from 15 seconds to 120 minutes. In
additional experiments, the binding of '251-SCH 23982 to BBM
with time was performed in ice when specific binding was
defined by 100 M SKF 82526 (a DA-1 agonist) using degassed
buffer.
To study the dissociation kinetics we used similar experimen-
tal conditions except that the membranes were preincubated
with 2 nM 3H-methyl-spiroperidol or 100 p '251-SCH 23982 for
60 minutes at 25°C in a shaking water bath before the addition
of unlabelled ligand (20 M trifluperidol or SCH 23982). The
unlabelled ligands were added as 1% of the total assay volume
to avoid dilution of the assay mixture which could possibly
disturb the binding equilibrium.
Competition studies. The ability of various antagonists to
compete with the specific binding of 2 nM of either 3H-
spiroperidol or 3H-methyl-spiroperidol or 50 to 75 M '251-SCH
23982 to BBM and BLM was studied under standard assay
conditions. The concentration of unlabelled antagonist ranged
from l0— to l0— M (11 to 22 concentrations). In the competi-
tion using agonists the buffer was degassed and experiments
performed at 4°C.
Calculations. Dissociations constants (Kd) were calculated
from kinetic data [15, 16] and Rosenthal plots [34]. Affinity
constants (K1), Kd and maximum receptor density (Bmax)were
analyzed by non-linear regression using the Lundon 1 and 2
program (Lundon Software).
Methods for the determination of adenylate cyclase activity
Freshly prepared membranes were washed three times in Tris
buffer and the final pellet was sonicated in Tris buffer for 30
seconds at setting #50 of a Branson Sonifier sonicator fitted
with a microprobe. Protein concentration was adjusted with
Tris buffer to yield 100 to 200 g protein/tube. A 40 d aliquot of
either BBM or BLM membranes was added to a reaction
mixture providing an ATP regeneration system (Tris-Cl 100
mM, 10 mM MgCI2, 0.1% BSA [RIA grade from Sigma], 10
IU/lOO pi creatine phosphokinase, 20 mri phosphocreatine, 0.1
mM GTP, 0.25 mM ATP [cAMP, calmodulin free], 0.4 mM
EGTA, 0.05 mri isobutylmethylxanthine, pH 7.5). An addi-
tional 20 pi of buffer or ligands to be studied were added. cAMP
levels were quantitated by radioimmunoassay using the gamma
flow as previously described [15, 16].
Determination of phospholipase-C activity
Phospholipase-C activity was determined using an exogenous
source of 3H-phosphatidylinositol-4,5-bisphosphate (PIP2; New
England Nuclear) as the primary substrate for PL-C as de-
scribed by Felder, Jose and Axelrod [35]. This assay was used
to monitor the hydrolysis of PIP2 alone, independent of the
hydrolysis of its natural precursors, phosphatidylinositol-4-
phosphate, and phosphatidylinositol.
Statistical analyses
All data are presented as mean standard error. Differences
between groups were analyzed by one-way ANOVA and sig-
nificance tested by Duncan multiple range test. Differences
within groups were determined by paired t-test with the Bon-
ferroni correction for multiple groups. A P value of less than
0.05 indicated significant changes.
Results
Purity of BLM and BBM
Separation and purification of BBM and BLM was assessed
biochemically by the activities of marker enzymes (Table 1).
Na/K ATPase, the marker for BLM was enriched 13.0-fold
over crude homogenate in the BLM preparation while it was
de-enriched in the BBM preparation by a factor of 5. Gamma-
glutamyl-transpeptidase (GT) a marker enzyme for BBM was
enriched 11.0-fold over crude homogenate in the BBM and was
slightly enriched in the BLM, suggesting a small contamination
of BBM. Alkaline phosphatase, another BBM marker enzyme,
was enriched 6.2-fold over crude homogenate. Alkaline phos-
phatase was enriched 2.6-fold in BLM as well, which, as seen
for GT, show slight contamination of BLM with BBM. The
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Table 2. Orientation of BLM
% Leaky % Inside-Out % Right side-out
Mean 57.4 16.0 26.6
SE 3.4 2.2 3.2
biochemical purity of the BBM and BLM preparations was
further evaluated by assays of other enzymes. Table 1 lists the
activities of lactate dehydrogenase, acid phosphatase, and
cytochrome-C-oxidase which are marker enzymes for cytosol,
lysosomes, and mitochondria, respectively. The de-enrichment
of the BLM and BBM over the crude homogenate for both LDH
and cytochrome c oxidase show little if any contamination of
these preparations by cytosol and mitochondria. Some contam-
ination of both BLM and BBM by lysosomes is shown by a lack
of dc-enrichment for acid phosphatase. These results are similar
to those described in canine renal membranes [22].
BLM vesicle orientation
We assessed the orientation of the basolateral membrane
vesicles in the final preparation as described in the Methods
section to determine if our preparation was similar to that
reported by other laboratories. Further, it needed to be dem-
onstrated that the basolateral membrane vesicles could be
completely disrupted by sonication. Complete disruption of the
vesicles would insure the availability of all surface receptors for
radioligand binding studies. BBM vesicles were completely
disrupted by sonication since there was no uptake of 22Na by
BBM (data not shown).
The orientation distribution of the BLM vesicles in our
preparation is summarized in Table 2. Most (57.4%) of the
preparation occurs as the leaky form. The distribution in the
inside out and right-side out orientations were 16.0% and
26.6%, respectively, which is consistent with previously re-
ported values [32]. Upon sonication for 30 seconds, essentially
all of the vesicles were converted to the leaky orientation.
Based on these studies, our membrane preparations were
sonicated before further analysis was performed in order to
provide all membrane surfaces access to added reagents.
Determination of the DA-1 and DA-2 receptors in BBM
andBLM
Kinetic analysis. The time course of the association of
3H-methyl-spiroperidol and '251-SCH 23982 with BBM and
BLM was measured over 120 minutes for total and non-specific
binding. Specific binding at steady state was about 60 to 70%
when antagonists were used to define non-specific binding;
when SKF 82526 was used to define non-specific binding,
specific binding was about 50%. The association was rapid and
reached steady state within 20 minutes. Dissociation reached
steady state within 30 minutes.
Binding isotherms. The most selective ligand for D-l recep-
tors in brain membranes is the antagonist SCH23390 [361.
Therefore we used this ligand to measure DA-l receptors in
BBM and BLM. (D-l refers to the central dopamine-l receptor
and DA-l refers to the peripheral dopamine-l receptor). DA-l
Vesicle orientation was determined as described in the Methods
section. Values are the mean SE of 4 experiments performed in
triplicate.
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Fig. 1. The plot of specifically bound '251-SCH 23982 vs. free radioli-
gand (A), log free ligand (B) and Rosenthal transformation of the data
(C) in hasolaterol membrane. Non-linear regression analysis reveals a
high and low affinity site.
receptors were measured using increasing concentrations of
DA-l specific antagonist '251-SCH 23982 (a compound of iden-
tical structure to SCH 23390 except the substitution with 1251 for
chloride at position #7). Sidhu, et al have suggested that this is
the radioligand of choice to study brain dopamine-l receptors
[38]. This radioligand has also been shown by Felder and Jose
to identify the rat renal DA-l receptor [391. Non-specific
binding was defined by the addition of 20 tM unlabelled SCH
23390 or 100 tM SKF 82526, a DA-1 agonist.
A typical binding isotherm for the DA-l antagonist '251-SCH
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Fig. 2. The plot of specifically bound '251-SCH 23982 vs. free radioli-
gand (A), log free ligand (B), and Rosenthal transformation of the data
(C) in brush border membrane. Non-linear regression analysis reveals a
high and low affinity size.
23982 is shown in Figures 1 and 2: In the top panel, specifically
bound '251-SCH 23982 is plotted against free ligand concentra-
tion for both brush border (Fig. 2) and basolateral membranes
(Fig. 1). The middle panel plots the specifically bound radioli-
gand with log free radioligand concentration. The bottom panel
is a plot of the data using a Rosenthal transformation [34]. The
Kd and Bmax values for BB (N = 4) and BL (N = 5) are shown
at the bottom panel and listed in Table 3. Non-specific binding
was defined by SCH 23390 unless otherwise specified. The
non-linear regression analysis fit the data to a high affinity
binding site and a very low affinity site. In some instances the
slope of the low affinity site was close to zero, which was
Table 3. Dissociation constant (Kd, nss) and maximum receptor
density (Bmx, fmol/mg protein)
Radioligand Membrane Kd Br,,ax N
'25l-SCH 23982 BBM
BLM
1.8
5.8
0.11
1.79
49 6
100 21
4
5
3H-methyl-spiroperidol BBM
BLM
8.4
8.1
2.9
4.2
298 140
372 233
6
6
3H-spiroperidol BBM
BLM
6.4
4.9
3.0
2.0
162 61
293 127
5
3
Values are mean SE. N = number of experiments. Data were
analyzed by non-linear regression of Rosenthal plots. As indicated in
the Results, the data best fit a high affinity binding site and a very low
affinity site; only the high affinity site is reported. Specific binding sites
using '25l-SCH 23982 were taken to indicate DA-1 receptors, while
specific 3H-methyl-spiroperidol or 3H-spiroperidol binding sites were
taken to indicate DA-2 receptors. Abbreviations are: BBM, brush
border membrane; BLM, basolateral membrane. There were no differ-
ences in Kd or between BBM and BLM.
essentially non-saturable by non-linear regression analysis.
Thus, only the value of the high affinity site is reported. The
determination of DA-2 receptors in both BBM and BLM was
accomplished by the use of either 3H-methyl-spiroperidol or
3H-spiroperidol. Both ligands have been shown to be selective
for DA-2 receptors but bind to serotonin-2 receptors as well.
However, in our system ketanserin, a serotonin-2 antagonist,
did not compete effectively for either 3H-spiroperidol or
methyl-spiroperidol binding. 3H-methyl-spiroperidol has a
higher specific activity (80 Ci/nmol) than 3H-spiroperidol (20
Ci/nmol). Non-specific binding was defined by 20 M triflu-
peridol, a DA-2 antagonist, which was shown to compete
effectively for spiroperidol binding by competition analysis.
Since spiroperidol has also a high affinity to the serotonin
receptor, trifluperidol was chosen to define non-specific bind-
ing; trifluperidol has a weak affinity for the serotonin receptor
[37]. Both 3H-methyl-spiroperidol and 3H-spiroperidol binding
were analyzed by non-linear regression analysis. The Kd and
Bmax values for the high affinity site were similar with the use of
3H-methyl-spiroperidol and 3H-spiroperidol in both BBM and
BLM. Table 3 summarizes the K and Bmax determined from
the binding isotherms of the DA-l antagonist '251-SCH 23982
and the DA-2 antagonists 3H-methyl-spiroperidol and 3H-spiro-
peridol. The primary data were analyzed by a non-linear fitting
routine as explained in Methods and consisted of a high affinity
site and a very low affinity site. In most instances the slope of
the low affinity site was close to zero, which was essentially
non-saturable by non-linear regression analysis. Thus, only the
value of the high affinity site is reported. The receptor Kd and
Bmax were similar for both the DA-l and DA-2 receptor in BBM
and BLM.
Competition studies. The ability of various antagonists to
compete for the binding of the DA-l antagonist '251-SCH 23982
is shown in Figure 3 for BBM. The K and receptor number are
summarized in Tables 4 and 5. In both membranes the compe-
tition curves for the DA-! antagonists SCH 23390 and SKF
103108A, the serotonin-2 antagonist, ketanserin, and beta ad-
renergic antagonist (—)-propranolol revealed a low affinity and
high affinity site. Both high and low affinity sites for the DA-l
antagonists had lower K than that noted for the non-dopamin-
ergic antagonists. The alpha adrenergic antagonist, phentol-
2.
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Fig. 3. Competition for '251-SCH 23982 specific binding sites in
brush border membranes. The values are means SEM for 3 to 5
experiments performed in triplicate using 11 to 22 drug
concentrations. A. Competition experiments showing
stereoselectivity. Symbols are: (0) (R)-SCH 23390; (U) (S)-SCH
23388. B. Competition experiments using antagonists. Symbols are:(•—) SKF 103108A; (0—0) (R)-SCH 23390; (L—L)
propanolol; (0---0) ketanserin; (A---A) phentolamine. C.
Competition experiments using agonists. The plot for (R)-SCH
3 23390 (0—0) is added for comparison. Symbols are: (A---A)
dopamine; (• •) SKF 82526).
Table 4. Inhibition constant (K1, M) and receptor number (R0, fmol/mg protein) for drugs competing for specific '251-SCH 23982 binding sites
in BBM
Drug
Low affinity High affinity
Receptor selectivityK R0 K R,,
Antagonists
R-SCH 23390 4.0 1.2 E7 22 6 4.1 0.4 E9 34 1 DA-l
S-SCH 23388 6.0 0.8 E7 69 2 — — Inactive
SKF 103108A 1.5 0.3 E7 22 1 1.5 0.3 E9 16 3 DA-1
Ketanserin 3,0 1.4 E4 25 2 7.5 0.2 E6 14 4 serotonin-2
Phentolaminea 5.0 0.0 E 47 4 — — a-adrenergic
(—)-Propranolol 5.0 0.0 E4 15 3 2.1 1.2 E 23 I i3-adrenergic
Agonists
SKF 82526 1.3 0.4 E5 18 0.2 8.3 0.8 E8 21 0.1 DA-l
Dopamine 1.3 0.0 E4 67 15 4.0 1.0 E7 49 16
Serotonin > l0 M
The respective values for low and high affinity sites are tabulated. Values are mean SE for 3 experiments per drug except for ketanserin,
phentolamine, (—)-propranolol where N = 2. For serotonin one study did not show competitive inhibition at l0- M. Twenty-two drug
concentrations were used per study. Data were analyzed by non-linear regression. The assignment to DA- 1, adrenergic or serotonin selectivity is
not meant to ignore affinity to other receptors. The non-DA effects are considered in the discussion.
a Only one affinity site was detected
amine delineated only one site, the K of which was greater than
that noted for the dopaminergic antagonists. The competition
experiments with DA-1 agonist SKF 82526 and DA also re-
vealed a high and low affinity binding site with SKF 82526
competing more effectively than DA. Serotonin was a poor
competitor for specific '251-SCH 23982 specific binding sites.
Stereoselectivity was also demonstrated since (R)-SCH 23390
was more effective than (S)-SCH 23388 (the inactive stereoiso-
mer) in competing for specific '251-SCH 23982 binding sites.
Table 6 summarizes the K1 for both membranes in the
competition experiments using 3H-spiroperidol. In BBM the
DA antagonist array was spiroperidol > haloperidol = triflu-
A
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Table 5. Inhibition constant (K1, M), and receptor number (R0, fmol/mg protein) for drugs competing for specific
in BLM
'251-SCH 23982 binding sites
Drug
Low affinity High affinity
Receptor selectivityK1 R0 K1 R0
Antagonists
R-SCH 23390 3.0 0.9 E7 14 2 5.0 0.9 E9 41 3 DA-l
S-SCH 23388 5.7 0.5 E7 61 i — Inactive
SKF 103108A 2.5 0.2 E7 20 7 1.2 0.2 E9 16 4 DA-l
Ketanserin 3.0 1.4 E4 27 0.1 2.0 0.7 E6 20 0.1 serotonin-2
Phentolaminea 2.8 1.6 E5 30 I — — a-adrenergic
(—)-Propranolol 5.0 0.0 E4 15 1 5.1 0.0 E5 34 6 13-adrenergic
Agonists
SKF 82526 6.5 1.8 E6 12 0.1 4.5 1.8 E8 14 I DA-l
Dopamine 5.0 0.0 E4 44 10 2.0 1.2 E7 30 12
Serotonina 5 E5 85
The respective values for low and high affinity sites are tabulated. Values are mean SE for 3 experiments per drug except for ketanserin,
phentolamine, (—)-propranolol where N = 2, and serotonin where N = 1. Twenty-two drug concentrations were used per study. Data were
analyzed by non-linear regression. The assignment to DA-I, adrenergic or serotonin selectivity is not meant to ignore affinity to other receptors.
a Only one affinity site was detected
Table 6. Inhibition constant (K1, M) for drugs competing for specific
3H-spiroperidol binding site
Drug BBM BLM Receptor selectivity
Spiroperidol 9.6 3.0 E—8 8.2 3.9 E8 DA-2 > DA-l
Haloperidol 5.0 1.2 E7 2.6 0.2 E7 DA-2 > DA-l
Trifluperidol 4.0 0.9 E7 7.6 0.3 E7 DA-2> DA-l
Piflutixol 1.0 0.0 E6 2.0 0.8 E6 DA-I > DA-2
Chlorpheniramine 7.3 3.1 E 1.6 1.0 E4 Histamine-I
Phentolamine 2.3 1.4 E4 5.0 2.6 E5 a-adrenergic
(—)-Propranolol
Ketanserin
1.4 0.8 E4
5.0 E4
4.8 1.1 E5
5.0 E4 f.-adrenergicSerotonin-2
Values are mean SE for at least 3 experiments per drug except for
ketanserin where N = I performed in triplicate. Eleven to 12 drug
concentrations were used per study. Data were analyzed by non-linear
regression. The assignment to DA-l, adrenergic or serotonin selectivity
is not meant to ignore affinity to other receptors. The non-DA effects
are considered in the Discussion.
peridol> piflutixol. In the BLM the DA antagonist array was
spiroperidol> haloperidol = trifluperidol > piflutixol. In both
membranes the competition studies were indicative of a DA-2
receptor. Chiorpheniramine, phentolamine, and (—)-proprano-
lol, which are histamine-i, alpha-1/alpha-2, and beta-l/beta-2
antagonists, respectively, were poor competitors in both mem-
branes. In BBM chiorpheniramine competed more effectively
than the adrenergic blockers for specific 3H-spiroperidol bind-
ing sites; the converse was true for BLM. Ketanserin, a
serotonin-2 antagonist, competed weakly for specific 3H-spiro-
peridol binding sites in both BBM and BLM.
Adenylate cyclase studies
Occupation of DA-i receptors have been shown to increase
cyclase activity in all tissues studied including renal vessels and
tubules [15, 16, 18, 351. DA-2 receptors have been shown to
decrease the activity of cyclase in certain tissues and have no
effect in others [16, 18]. To further establish the presence of
DA-l receptors in both BLM vesicles and BBM vesicles we
determined if DA-i-stimulated adenylate cyclase activity was
present in either of these membranes. Figure 4A demonstrates
a concentration dependent increase in cAMP accumulation with
the addition of increasing DA concentration; the ECSO for BBM
and BLM are also listed. The presence of DA-stimulated
adenylate cyclase activity in the BBM could not be due entirely
to contamination from BLM because little contamination of
BBM with BLM is indicated by marker enzyme analysis (Table
1). The maximal increase in DA-stimulated adenylate cyclase
activity over basal activity is about 30%. The modest increase
could be in part due to the purification procedure used for the
membranes.
The presence of a DA-l receptor-linked adenylate cyclase
activity in BBM and BLM was further substantiated by the
ability of the DA- I selective antagonist SCH 23390 to block the
DA-stimulated adenylate cyclase activity (Fig. 4B). The IC50
values are listed in Figure 4B. The antagonist blocked the DA
associated stimulation completely to basal activity.
Further studies were done to determine if the DA stimulation
of adenylate cyclase activity was mediated by beta receptors,
which have also been shown to stimulate adenylate cyclase
activity. Tubular membranes taken from the fraction just prior
to Percoll gradient separation were used for these studies.
DA-stimulated adenylate cyclase activity at 5 x l0— M was not
affected by the addition of the beta receptor antagonist propran-
olol over the concentration range tested, yet was blocked by the
addition of SCH 23390 (DA-1 antagonist) in a concentration
dependent manner (Fig. 4C). The IC50 for SCH 23390 is 1.0
0.5 X iO M (N = 3). Therefore, DA-stimulated adenylate
cyclase activity is not due to occupation of beta adrenoceptors.
The beta adrenergic agonist isoproterenol stimulated adenylate
cyclase activity which was blocked by the beta receptor antag-
onist propranolol in a concentration dependent manner (IC50 =
1.1 0.5 x l0— M, N = 3), but was not affected by the DA-l
antagonist SCH 23390 over the concentration range tested (Fig.
4D). Thus the dopamine and isoproterenol stimulate adenylate
cyclase activity by occupation of specific receptors.
Determination of phospholipase-C activity
DA-stimulated phospholipase-C activity was determined in
both BBM and BLM. Figures 5 and 6 show the concentration
dependent release of total inositolphosphates from 3H-PIP2 for
DA- and DA-l agonist SKF 82526-stimulated phospholipase-C
activities in BBM (Fig. 5) and BLM (Fig. 6). DA-stimulated and
0
0.
E
E
0
E0.
Log [antagonist], M Log [antagonist], M
Fig. 4. Adenylate cyclase studies in BB (0, brush border membrane) and BL (•, basolateral membrane). The values are means SEM for at least
3 experiments performed in triplicate. Statistical significance determined by ANOVA, Dunnett's test. A. The effect of DA on adenylate cyclase
activity in BB (ECSO, 7.9 0.5 x lO M) and BL (EC50, 1.1 0.4 x 10 M). In BB, DA concentrations of IO M or greater were significantly
different from basal values. In BL, DA concentrations of lO M or greater were significantly different from basal values (P < 0.05). B. The effect
of the DA-1 antagonist SCH 23390 on DA-stimulated adenylate cyclase activity in BB (IC50, 2.1 0.5 x 106) and BL (IC50, 2.5 0.5 x l0—).
In BB, DA (l0- M) increased adenylate cyclase activity (P < 0.01 compared to basal). The DA-l antagonist SCH 23390 antagonized the
DA-stimulated adenylate cyclase activity in a concentration dependent manner such that at iO M or greater, DA-stimulated adenylate cyclase
activity was no longer different from basal levels in BB and BL. C. The effect of the DA-l antagonist SCH 23390 (•) or the beta adrenergic
antagonist (—)-propranolol (0) on DA-stimulated adenylate cyclase activity in renal cortical membranes. The DA-1 antagonist SCH 23390 blocked the
DA-1-stimulated adenylate cyclase activity in a concentration dependent manner such that at lO st or greater, adenylate cyclase activity in the presence
of DA was no longer different from basal values. Propranolol had no effect on DA-stimulated adenylate cyclase activity. D. The effect of the DA-1
antagonist SCH 23390 (0) or the beta adrenergic antagonist (—)-propranolol (I) on isoproterenol-stimulated adenylate cyclase activity in renal cortical
membranes. The beta adrenergic antagonist propranolol blocked the isoproterenol-stimulated adenylate cyclase activity in a concentration dependent
manner such that io M or greater, adenylate cyclase activity is not longer different from basal values. SCH 23390 had no effect on DA-stimulated
adenylate cyclase activity.
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laboratories using a similar technique [19, 23]. The BBM were
more easily purified and had minimal contamination from BLM.
BLM were slightly contaminated with BBM which had to be
considered when comparing data between the membrane types.
DA receptors of both the DA-1 and DA-2 subtypes have been
previously identified in rat and rabbit renal homogenates. DA-1
receptors have also been reported in PT [15, 17] but the
distribution in BBM and BLM has not been investigated. DA-l
and DA-2 receptor subtypes appear to be present in both BBM
and BLM. Bmax values for both DA-l and DA-2 receptors were
in the range of fmol/mg protein in both BBM and BLM, which
are typical densities for high affinity selective DA receptors as
previously reported in brain [38]. The Kd for both DA-2 and
DA-1 receptors is about a log greater than that reported for
brain [37, 38] as previously reported by Felder and Jose [39].
The DA-2 binding sites were identified by two similar DA-2
antagonists 3H-spiroperidol and 3H-methyl-spiroperidol. In
both BBM and BLM specific binding of these DA-2 antagonists
was saturable with time and with ligand concentration and
demonstrated appropriate stereoselectivity as well as antago-
nist rank order potency for binding to a DA-2 receptor. The
kinetics of association and dissociation of 3H-methyl-spiro-
peridol in both BBM and BLM indicated the presence of a high
affinity receptor that saturated quickly, was reversible and
remained at steady state for as long as 120 minutes. Effective
competition of DA-2 antagonists but not alpha, beta, histamine,
or serotonin antagonists for specific DA-2 binding sites in BBM
and BLM further suggested the presence of DA-2 receptors.
Spiroperidol, used in our studies as a DA-2 antagonist, has been
shown to be partially selective for serotonin-2 receptors in some
membrane systems. In our system, however, it was not. In both
BBM and BLM, the serotonin-2 antagonist ketanserin did not
compete effectively for 3H-spiroperidol binding, The beta ad-
renergic antagonist (—)-propranolol which has M affinities to
the serotonin-l receptor, also did not compete effectively for
specific 3H-spiroperidol binding sites. In addition, Rosenthal
[34] plots of specific binding in either BBM and BLM were not
altered when serotonin-2 receptors were pre-blocked with ket-
anserin.
In BBM and BLM specific binding of the DA-l antagonist
'25I-SCH 23982 was saturable with time and with ligand con-
centration and demonstrated appropriate stereoselectivity as
well as antagonist rank order potency for binding to a DA-1
receptor. Effective competition of DA-1 antagonists, but not
alpha or beta adrenergic antagonists or DA-2 antagonists, for
specific '251-SCH 23982 binding in BBM and BLM further
suggested the presence of DA- 1 receptors. Neither serotonin
nor the serotonin antagonist, ketanserin, was effective in com-
peting for '251-SCH 23982 binding sites. This binding pattern is
unlike that seen in brain, where this radioligand can also label
serotonin binding sites [40, 41]. In rat kidney slices '251-SCH
23982 labels specific binding sites mainly in cortex [17] while
3H-spiroperidol labels specific binding in both cortex and me-
dulla [42]. If these ligands bound to serotonin sites rather than
dopamine binding sites, one would have expected similar
binding distribution for 1251-SCH 23982 and 3H-spiroperidol.
In the competition studies using SCH 23982 and SKF
103 108A, two binding sites were noted. Other investigators
have previously noted two binding sites for radio SCH 23982 or
23390 in brain [38, 43, 44]. There are studies to suggest that
there are DA-1 like receptors (identified by 3H-SCH 23390) not
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Fig. 5. The effect of DA (, N = 3), the DA-1 agonist, SKF 82526 (,N = 3), or the DA-2 agonist LY 171555 (, N = 3)on phospholipase-C
activity in brush border membranes. Values are means SEM for 3
experiments performed in triplicate. The y axis starts at 750 cpmlmg
protein. The effects of DA and SKF 82526 were different from basal
values (0, N = 3) at 10 M or greater (P < 0.05, Dunnett's test).
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Fig. 6. The effect of DA (, N = 3), the DA-1 agonist, SKF 82526 (,N = 3), or the DA-2 agonist LY 17155 (0, N = 3) on phospholipase-C
activity in basolateral membranes, Values are means SEM for 3
experiments performed in triplicate. The y axis starts at 750 cpm/mg
protein. The effects of DA and SKF 82526 were different from basal
values (0, N = 3) at l0— M or greater (P < 0.05, Dunnett's test).
SKF 82526-stimulated release of inositolphosphates increased
with increasing concentration. The DA-2 agonist LY 171555 did
not stimulate phospholipase-C activity over basal, in either
membrane, over the concentration range tested (Figs. 5 and 6).
We have previously reported that DA- 1 stimulated phospholi-
pase-C activity was blocked by the DA-1 antagonist SCH 23390
but not by the alpha1 adrenergic antagonist, prazosin or the
non-subtype-selective alpha adrenergic antagonist, phentol-
amine [35]. The phospholipase-C activity in BLM appears to be
considerably more than that seen in BBM.
Discussion
BBM and BLM were obtained primarily from proximal
tubule (PT) isolated from the outer renal cortex using a differ-
ential centrifugation-Percoll gradient method [19—21]. This
preparation had the advantage of purifying both BBM and BLM
from the same kidney cortical sample and thus allowed a valid
comparison between the two membrane types of all the mea-
sured parameters. The membrane purity, verified by assaying
for marker enzyme activity, was in agreement with several
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linked to the adenylate cyclase system [44]. In our studies the
low affinity site detected by SCH 23982 and SKF 103 108A was
similar to the high affinity site detected by the serotonin-2
antagonist ketanserin. It is possible that these sites may identify
the serotonin-2 site (responsible for the very low affinity site,
see below). It is also possible that one DA-1 affinity site is
linked to adenylate cyclase while the other DA-l affinity site is
linked to phospholipase-C activation. Analyses of the Rosen-
thal plots best fit a two component model, one with a high
affinity site and another with a very low affinity site. Only the
high affinity site was chosen to be indicative of DA receptors.
The Kd and Bmax ofboth DA- 1 and DA-2 receptors were similar
in BBM and BLM, although there was a tendency for a higher
density of DA receptors in BLM than BBM. Although the
membranes were not completely free of contamination from
each other and from other organelles, the similarity of values
would indicate that contamination need not preclude the above
conclusion, since the BBM was relatively free of BLM contam-
ination while the BLM had a minor degree of contamination
with BBM as judged by marker enzymes. The presence of
either DA- 1 and DA-2 receptors in both membrane types could
not be solely due to contamination since in the 3H-spiroperidol
studies the rank order potency for the histamine, alpha, and
beta adrenergic antagonists were so different between BBM and
BLM that contamination of one membrane with another could
not explain our finding of the presence of both DA receptor
subtypes in both membranes. Difference in affinities for (—)-
propranolol between BLM and BBM was also noted in the
'251SCH 23982 studies. The patterns of adenylate cyclase and
phospholipase-C activation by DA were also different in BBM
and BLM, further supporting the notion that the presence of
DA receptors in both membrane preparations was not due to
membrane contamination.
The presence of DA-l receptors in BBM and BLM was
further demonstrated by their linkage to adenylate cyclase
activity. Kebabian et al [40] previously proposed that DA
receptor subtype D-1 (designation in brain) was linked to
stimulation of adenylate cyclase but subtype D-2 (designation in
brain) was not linked to stimulation or linked to the inhibition of
adenylate cyclase activity. DA stimulated adenylate cyclase
activity in both BBM and BLM. This stimulation was specific,
as it was inhibited by the DA-1 antagonist SCH 23390 but not by
the beta-adrenergic antagonist propranolol. Stimulation of ade-
nylate cyclase activity in renal cortical membranes by the beta
adrenergic agonist, isoproterenol was also specific, as it was
inhibited by propranolol but not by SCH 23390. These results,
combined with the radioligand binding studies, indicate that
DA-1 receptors are present in both the BBM and BLM. The
DA-2 receptor in the kidney may not be linked to inhibition of
adenylate cyclase and its role in renal function has yet to be
established.
Another enzyme associated with neurotransmitter receptors
is phospholipase C [45]. Certain neurotransmitters stimulate
this enzyme, resulting in the hydrolysis of inositolphospholipids
to form inositolphosphates and diacylgycerol, which serve as
intracellular messengers. Phospholipase-C exists as both a
soluble and a membrane-bound enzyme and no functional
difference between the two types has been reported [46]. It is
assumed that the soluble form was removed during our prepa-
ration of BBM and BLM and, therefore, the only form active in
our system was the membrane bound form. Occupation of the
D-2 receptor by agonists in the anterior pituitary has been
reported to decrease phosphoinositide turnover [47]. The effect
of D- 1 receptors on phospholipase-C activity has not been
reported. These studies show that DA-1 but not DA-2 agonist
increase phospholipase-C activity in BBM and BLM. We have
previously reported the effect of DA- 1 but not DA-2 agonist-
stimulated phospholipase-C activity in renal membranes [35].
The DA-l stimulated phospholipase-C activity was blocked by
the DA-l antagonist SCH 23390 but not by the alpha adrenergic
blockers phentolamine and prazosin.
The role of DA receptors on electrolyte transport was not
determined in this study. Previous studies in rat and rabbit
kidney indicate that DA- 1 receptors are associated with a
decrease in sodium/fluid transport across the BLM [8, 10, 11].
This effect has been linked to a decrease in Na/K ATPase
activity apparently due to stimulation of an inhibitory G protein
[48]. In the rabbit intestine, a DA receptor other than the DA-l
receptor (at the serosal surface) is associated with an increase in
sodium and chloride transport [13]. In rabbit and rat DA has
been reported to have either no effect [8] or increased transport
[12, 14]. However, the DA receptor subtype mediating these
effects has not been described. Preliminary studies from our
laboratory indicate that DA- 1 receptors are associated with
inhibition of the Na/H antiport [49]. It is of interest to note
that parathormone, which, like DA-l agonists, stimulates both
adenylate cyclase and phospholipase-C activities [50], inhibits
Na/H antiport in rat renal BBM [51].
Summary
Dopamine-1 and dopamine-2 receptors are present in both
basolateral and brush border membranes in the dog. Dopamine-
I but not dopamine-2 receptors are linked to stimulation of both
adenylate cyclase and phospholipase-C systems. The role of
these receptors in renal tubular transport remains to be deter-
mined.
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